2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis.
Heart Lung Circ
; 33(4): 420-442, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38570258
ABSTRACT
Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Consensus
/
Amyloidosis
/
Cardiomyopathies
Limits:
Humans
Country/Region as subject:
Oceania
Language:
En
Journal:
Heart Lung Circ
Journal subject:
ANGIOLOGIA
/
CARDIOLOGIA
Year:
2024
Document type:
Article
Country of publication: